Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 10/20 | 0.44 |
| ▸ | HTR7 | P34969 | 10/20 | 0.44 |
| ▸ | DRD2 | P14416 | 4/20 | 0.44 |
| ▸ | HTR6 | P50406 | 2/20 | 0.44 |
| ▸ | BRD4 | O60885 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24309659 | 0.88 | HTR1A (0.43) | HTR1AHTR7DRD2HTR6HTR2A | |
| SCHEMBL29567073 | 0.88 | HTR1A (0.43) | HTR1AHTR7DRD2HTR6HTR2A | |
| SCHEMBL26808415 | 0.87 | SMN1; SMN2 (0.45) | HTR1AHTR7DRD2HTR6BRD4 | |
| SCHEMBL29567008 | 0.87 | TDP1 (0.45) | BRD4TDP1LMNAHTTSCN9A | |
| SCHEMBL24309354 | 0.87 | TDP1 (0.45) | BRD4TDP1LMNAHTTSCN9A | |
| SCHEMBL24309753 | 0.86 | HTR6 (0.41) | HTR1AHTR7DRD2HTR6BRD4 | |
| SCHEMBL29567208 | 0.86 | HTR6 (0.41) | HTR1AHTR7DRD2HTR6BRD4 | |
| SCHEMBL26808373 | 0.85 | HTR1A (0.41) | HTR1AHTR7DRD2HTR6HTR2A | |
| SCHEMBL26812870 | 0.85 | TDP1 (0.47) | BRD4TDP1LMNAHTTSCN9A | |
| SCHEMBL26808397 | 0.84 | HTR1A (0.44) | HTR1AHTR7DRD2HTR6HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230373935-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS, SAN DIEGO | 2023-11-23 | — | — | US | disclosed |
| US-20230373935-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS, SAN DIEGO | 2023-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230373935-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1G, SCNN1B | HTR1A 4018/4885HTR7 3833/4885DRD2 4505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.